ERBB2 and breast carcinoma: Interestingly, the finding that p110α inhibition leads to reactivation of PI3K signaling via p110β suggests that a concomitant inhibition of both isoforms serves to more efficiently block PI3K-dependent oncogenic signaling in HER2+ breast cancer models (35, 36).